Abstract: The present invention relates to a process for the preparation of compounds of formula I
wherein R1 and R2 are as defined in the specification as well as to the novel intermediates obtained by said process.
Abstract: Taxol (I) is a complex deterpene which is currently considered the most exciting lead in cancer chemotherapy. Taxol possesses high cytotoxicity and strong antitumor activity against different cancers which have not been effectively treated by existing antitumor drugs. However, taxol has a problem with solubility in aqueous media, which may impose some serious limitation in its use. Taxotére (III) seems to have antitumor activity superior to taxol with better bioavailability. Taxotére has a modified taxol structure with a modified C-13 side chain. This fact strongly indicates that modification on the C-13 side chain would provide a new series of taxol and Taxotére analogues which may have higher potency, better bioavailability and less unwanted toxicity. The present invention provides efficient and practical methods for the syntheses of Taxotére and its analogues through &bgr;-lactam intermediates and their coupling with baccatin III.
Type:
Grant
Filed:
February 29, 2000
Date of Patent:
April 17, 2001
Assignee:
The State University of New York at Stony Brook
Abstract: The present invention relates to dioxocyclopentyl hydroxamide derivatives of the formula
wherein X, Z and Q are as defined in the specification, and to pharmaceutical compositions and methods of treatment thereof.
Abstract: In accordance with the present invention, methods have been developed for the reduction of the chloride content of epoxy compound starting materials. Invention methods comprise subjecting specifically defined combinations comprising an epoxy resin starting material and other components to conditions sufficient to produce a treated epoxy compound (i.e., an epoxy compound having a chloride content which is reduced relative to that of the epoxy resin starting material), and separating the treated epoxy compound from the combination. Other components contemplated for use in the practice of the present invention comprise, alternatively, mixtures of crown ether, organic solvent and suitable base; mixtures of crown ether-like solvent and suitable base; mixtures of aprotic solvents and hydrides (other than tin hydride); mixtures of nonhalogenated organic solvent and reducing metal; and the like. In accordance with a further aspect of the present invention, products (i.e.
Abstract: The present invention is a process for the preparation of a compound of the formula:
where R3, R4 and n are defined in the specification which comprises hydrogenating a compound of the formula:
the E-geometrical isomer thereof or a mixture of the Z- and E-isomers in the presence of catalyst containing Rh, a chiral ligand with at least one phosphorous atom where the hydrogenation is conducted in the presence of a base.
Type:
Grant
Filed:
March 14, 2000
Date of Patent:
April 3, 2001
Assignee:
Pharmacia & Upjohn Company
Inventors:
Mark J. Burk, Nicholas B. Johnson, Bradley D. Hewitt
Abstract: A bisphenol derivative represented by the following formula and a manufacturing method thereof are disclosed.
where R is a lower alkyl group, tetrahydropyranyl, methoxymethyl or trialkylsilyl group, and the benzene rings in the formula may be substituted by a lower alkyl group.
Abstract: A process for the preparation of 3-substituted 4-cyano-pyrrole compounds of the formula (I)
in which
Ar has the meaning given in the description, by reaction in a 1st stage of bromides (II)
Ar—Br (II)
with acrylonitrile in the presence of a solvent and a suitable reaction auxiliary to give acrylonitrile derivatives (III)
Ar—CH═CH—CN (III)
and in a 2nd stage with a phenylsulphonylmethyl isocyanide (IV)
Ph—SO2—CH2—CN (IV)
in the presence of a solvent and optionally in the presence of a suitable reaction auxiliary, characterised in that the the 1st stage is carried out in the presence of a palladium catalyst and the 2nd stage in the presence of a 1.2- to 1.8-fold molar excess of alkali metal alcoholate or alkali metal hydroxide.
Type:
Grant
Filed:
July 1, 1993
Date of Patent:
March 20, 2001
Assignee:
Bayer Aktiengesellschaft
Inventors:
Peter C. Knüppel, Reinhard Lantzsch, Klaus Jelich, Peter Andres, Albrecht Marhold
Abstract: The present invention concerns novel 7-ethers of taxane derivatives, their use as antitumor agents and pharmaceutical compositions containing the novel compounds.
Abstract: Methods for the preparation of (2S,3S)-1,5-benzothiazepine derivatives of the formula (II) and isomers thereof, and for the preparation of (2R,3R)-1,5-benzothiazepine derivatives of the formula (III) and isomers thereof,
wherein ring A and ring B are independently a substituted or unsubstituted benzene ring, and R2 is a 2-(dimethylamino)ethyl group or a group of the formula:
or a pharmaceutically acceptable salt thereof.
Abstract: 4-acetoxy-2&agr;-benzoyloxy-5&bgr;, 20-epoxy-1&bgr;, 7&bgr;, 10&bgr;-trihydroxy-9-oxo-11-taxen-13&agr;-y1(2R,3S)-3-t-butoxycarbonylamino-3-phenyl-2-hydroxypropionate trihydrate obtained by a process of centrifugal partition chromatography.
Type:
Grant
Filed:
August 20, 1999
Date of Patent:
March 6, 2001
Assignee:
Rhone-Poulenc Rorer S.A.
Inventors:
André Durand, Alain Gerbaud, Rodolphe Margraff
Abstract: Processes for the preparation of taxol and other taxanes through selective derivatization of the C(7) and C(10) hydroxyl groups of 10-DAB, particularly a novel process using a new strategy in which the C(10) hydroxyl group is protected or derivatized prior to the C(7) hydroxyl group; and the provision of C(7) and C(10) derivatized 10-DAB compounds.
Type:
Grant
Filed:
June 17, 1999
Date of Patent:
February 20, 2001
Assignee:
Florida State University
Inventors:
Robert A. Holton, Zhuming Zhang, Paul A. Clarke
Abstract: The present invention describes for the first time the design and synthesis of a soluble tumor-directed paclitaxel prodrug which may establish a new mode of utilization of the taxane class of anticancer agents in cancer therapy.
Abstract: The present invention provides convergent processes for preparing myxopyronins and corallopyronins, compounds useful as antibacterial therapeutics. The present invention also provides novel compositions of matter which are useful for the preparation of pyronin antibiotics.
Abstract: A titanium-containing solid catalyst used for producing an oxirane compound by reacting an olefin type compound with an organic hydroperoxide, wherein the catalyst is obtainable by at least one method selected from the following (1) to (3):
(1) a titanium compound is supported on silica having an average pore diameter (D) measured by a mercury pressing method of 5 nm or more and having pore distribution in which at least 60% of pore volume is composed of pores having a pore diameter within the range of D±0.3 D (nm), and is calcined
(2) silica is impregnated in water, then dried, and a titanium compound is supported on the silica, then calcined,
(3) silica is impregnated in a titanium-containing impregnation solution satisfying the following [formula-1], and is calcined
A/B≦0.2 [formula-1]
A: mol number of metal titanium in the impregnation solution
B: mol number of a silanol group existing in silica.
Abstract: A process for the preparation of I:
in which R and R1 have the meanings reported in the description, that comprises the enzymatic kinetic resolution by transesterification with aminoalcohols of 3-phenylglycidates of formula I:
is described.
Type:
Grant
Filed:
September 20, 1999
Date of Patent:
February 13, 2001
Assignee:
Zambon Group S.p.A.
Inventors:
Marco Villa, Dario Tentorio, Angelo Restelli, Sergio Riva
Abstract: A method of recovering benzyl alcohol, gamma butyrolactone, or propylene carbonate from an impure effluent stream of an industrial process is provided. The effluent waste stream contains greater than about 10 percent by weight of monomeric units that are reacted to form larger oligomers and polymers. The first step in the recovery process involves polymerizing the monomeric units present in the effluent waste stream under conditions effective to reduce the concentration of monomeric units in the waste stream to less than about 10 weight percent. The waste stream then is fed to a first separation stage where it is separated into (i) a gaseous stream of water, soluble gases, and volatile contaminants and (ii) a suspension comprising the high boiling solvent, semi-volatile materials, and non-volatile contaminants and materials. Then the dewatered, low vapor pressure, high boiling solvent-containing suspension is either distilled or evaporated to separate the high boiling solvent from non-volatile materials.
Type:
Grant
Filed:
November 6, 1998
Date of Patent:
February 13, 2001
Assignee:
International Business Machines Corporation
Abstract: Novel reaction conditions for the cleavage of silyl ethers from silyl protected taxane precursors to afford paclitaxel and paclitaxel analogues in high yield and quality are described. Paclitaxel is prepared from a taxane precursor by treating the taxane precursor with a strong acid such as trifluoroacetic acid in a solvent such as aqueous acetic acid, such that the amount and number of side reactions and taxane impurities are significantly minimized. Also desribed are the crystallization methods for the isolation of paclitaxel in either of the two crystal forms A or B. Paclitaxel and paclitaxel analogues are anti-cancer agents.
Type:
Grant
Filed:
May 16, 2000
Date of Patent:
February 6, 2001
Assignee:
Bristol-Myers Squibb Company
Inventors:
Ambarish K. Singh, Raymond E. Weaver, Gerald L. Powers, Victor W. Rosso